# Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma

> **NCT05938387** · PHASE1 · COMPLETED · sponsor: **CureVac** · enrollment: 37 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **BIOLOGICAL:** CV09050101 mRNA vaccine (CVGBM) 12 μg
- **BIOLOGICAL:** CV09050101 mRNA vaccine (CVGBM) 25 μg
- **BIOLOGICAL:** CV09050101 mRNA vaccine (CVGBM) 50 μg
- **BIOLOGICAL:** CV09050101 mRNA vaccine (CVGBM) 100 μg
- **BIOLOGICAL:** CV09050101 mRNA vaccine RDE 100 μg
- **BIOLOGICAL:** CV09050101 mRNA vaccine (CVGBM) 6 μg

## Key facts

- **NCT ID:** NCT05938387
- **Lead sponsor:** CureVac
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-01
- **Primary completion:** 2026-02-02
- **Final completion:** 2026-02-02
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05938387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05938387, "Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05938387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*